Pfizer is set to construct a $350M biotechnology centre in China.


The new facility will represent the company’s third biotechnology centre across the world and the first in Asia and will include an advanced modular facility by GE Healthcare, based on flexible single-use bio-manufacturing technology.

The centre will accommodate the Pfizer China’s biosimilars and biologics quality, technical service, logistics and engineering divisions, in addition to commercial manufacturing. It will also serve as a process development and clinical supply site.

Pfizer Essential Health group president John Young said: “We believe that the Pfizer Global Biotechnology Center in Hangzhou will help support China’s aim to increase the complexity and value of its manufacturing sector by 2025, and contribute to building a truly innovative and vibrant biopharmaceutical industry.

“We are encouraged by a series of important reforms introduced by Chinese government that will further stimulate the industry to meet emerging health challenges, such as the rising incidence of non-communicable diseases and an aging population; as well as attract both domestic and foreign investment in healthcare and R&D.”

The facility is anticipated to be completed in 2018, creating more than 150 jobs in the region.